Regeneron Pharmaceuticals (REGN) DIvidends Date & History

Key Takeaways

• Regeneron Pharmaceuticals (REGN) initiated a quarterly dividend of $0.94 per share in early 2025, marking its entry into shareholder returns.
• Current forward annual dividend is $3.76, yielding approximately 0.50%.
• Payout ratio of 8.49% reflects outstanding earnings coverage and sustainability.
• Strong free cash flow exceeding $4 billion annually bolsters dividend reliability.
• Compared to biotech peers, REGN's yield is competitive amid many non-payers.
• Suitable for conservative dividend investors prioritizing safety over high income.

Dividend Overview

Regeneron Pharmaceuticals (REGN), a leading biotechnology company focused on innovative therapies, began paying dividends in 2025 after years of reinvesting profits into research and development. The company now distributes a quarterly dividend of $0.94 per share, resulting in an annual payout of $3.76 and a forward yield of 0.50%. The most recent ex-dividend date was February 20, 2026, with payment on March 5, 2026. This modest yield positions REGN as neither a high-yield stock nor a traditional dividend aristocrat, but rather a growth-oriented biotech offering initial income alongside capital appreciation potential. With its low payout commitment, the dividend complements REGN's strategy of balancing shareholder returns with heavy R&D investment in areas like oncology and immunology.

Dividend History and Growth

Prior to 2025, Regeneron Pharmaceuticals did not pay dividends, prioritizing growth in its pipeline of blockbuster drugs like Eylea and Dupixent. The initiation came alongside strong Q4 2024 earnings, with the board approving a quarterly payout of $0.94 per share starting in early 2025. Since then, payments have been consistent quarterly, with no increases or cuts recorded as of April 2026. The dividend lacks a long-term growth streak, but its stability over the past year signals a potential shift toward regular distributions. Future growth could depend on sustained revenue from collaborations and new approvals, aligning with the company's maturing profile.

Dividend Sustainability and Payout Ratio

Regeneron Pharmaceuticals' dividend is highly sustainable, underpinned by a payout ratio of just 8.49%—well below industry norms for safety. Earnings per share comfortably cover the dividend multiple times over, while free cash flow reached approximately $4.1 billion in the latest full-year period, far exceeding annual dividend obligations of around $400 million (based on shares outstanding). The company maintains a strong balance sheet with minimal debt relative to its $15+ billion in cash equivalents and low leverage. This financial stability, driven by high-margin products, supports ongoing payments even amid R&D fluctuations, making cuts highly unlikely in the near term.

Dividend Compared to Industry Peers

In the biotechnology and pharmaceuticals sector, REGN's 0.50% yield stands out positively against many growth-focused peers that pay nothing. For instance, Vertex Pharmaceuticals (VRTX) and Alnylam Pharmaceuticals (ALNY) offer 0% yields, prioritizing reinvestment. Larger established players like Amgen (AMGN) yield about 2.9%, and Gilead Sciences (GILD) around 3%, but these come with higher payout ratios. REGN's profile—modest yield with biotech-low payout—appeals to those seeking income without sacrificing growth exposure.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover hidden gems like sustainable dividend payers in biotech.

Is This Stock Attractive for Dividend Investors?

Regeneron Pharmaceuticals (REGN) may appeal to conservative dividend growth investors who value safety and total returns over high current income. Its ultra-low payout ratio and robust cash generation provide a wide margin for future increases, potentially building a compelling growth trajectory as the program matures. Income-focused retail investors might find the 0.50% yield too modest compared to mature dividend kings, but it serves as a reliable supplement for those holding for REGN's pipeline-driven appreciation. Long-term holders balancing biotech volatility with modest payouts could view it favorably, especially given superior coverage versus higher-yielding pharma peers. However, pure yield chasers may look elsewhere, as REGN remains growth-primary.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations